Comparison of the effects on coagulation function and safety of bivalirudin and heparin
Comparative study published in Medicine (2024)
Abstract
BACKGROUND: To analyze the effects on coagulation function and safety of bivalirudin and heparin in patients undergoing percutaneous coronary intervention (PCI) and provide clinical evidence for their application. METHODS: A total of 42 patients with coronary heart disease undergoing PCI treatment from July 2019 to January 2022 at Datong Third People's Hospital in China were divided into 2 groups: the bivalirudin group and the heparin group. The former received perioperative administration of bivalirudin, while the latter received heparin. After 24 hours of treatment, blood indicators, coagulation functions, as well as cardiac, hepatic, and renal markers were evaluated. Additionally, Thrombolysis In Myocardial Infarction (TIMI) flow graded infarct-related vessel blood flow was assessed in both groups. Adverse cardiovascular and cerebrovascular events were monitored for a duration of 12 months. RESULTS: The Activated clotting time (ACT), D-dimer (D-D), and prothrombin time (PT) levels in the bivalirudin group were significantly lower than those in the heparin group (P < .05). Both the bivalirudin and heparin groups showed significant improvement in TIMI flow grade after PCI (P < .05). The levels of Creatine Kinase-MB (CK-MB), N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in the bivalirudin group were significantly lower than those in the heparin group (P < .05). There were no serious adverse cardiovascular and cerebrovascular events in either group. CONCLUSION: Bivalirudin has a slightly superior impact on coagulation function and safety profile in patients undergoing PCI compared to heparin, and the preventive effect of both on postoperative cardiovascular events is similar.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Comparative analysis of coagulation function and safety endpoints between bivalirudin and heparin.
Por qué esto importa para la hirudoterapia
Este estudio comparó la bivalirudina frente a la heparina para la anticoagulación perioperatoria durante la intervención coronaria percutánea (ICP) en 42 pacientes con enfermedad coronaria, evaluando los marcadores de coagulación, los biomarcadores cardíacos, el grado de flujo TIMI y los eventos adversos cardiovasculares/cerebrovasculares durante 12 meses. La bivalirudina es un inhibidor directo de la trombina derivado estructuralmente de la hirudina, el anticoagulante presente en la saliva de la sanguijuela medicinal, por lo que los estudios clínicos sobre su desempeño son directamente relevantes para comprender cómo funcionan en la práctica los anticoagulantes inspirados en el secretoma de la sanguijuela. El grupo de bivalirudina mostró niveles significativamente menores de tiempo de coagulación activado, dímero D, tiempo de protrombina, CK-MB y NT-proBNP en comparación con la heparina, con ambos grupos mostrando una mejora del flujo TIMI y sin eventos adversos graves. Sin embargo, se trata de un estudio unicéntrico con una muestra pequeña de 42 pacientes y sin seguimiento a largo plazo más allá de los 12 meses, por lo que sus hallazgos son exploratorios más que evidencia definitiva de superioridad.
Citación
Comparison of the effects on coagulation function and safety of bivalirudin and heparin.
Wang et al. · Medicine, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026